GIC 102
Alternative Names: GIC-102Latest Information Update: 15 Jul 2024
At a glance
- Originator GICELL
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Preclinical Haematological malignancies
Most Recent Events
- 31 May 2024 Preclinical trials in Haematological malignancies (Combination therapy) in South Korea (Parenteral) prior to May 2024
- 31 May 2024 Preclinical trials in Solid tumours (Combination therapy) in South Korea (Parenteral) prior to May 2024
- 31 May 2024 Updated efficacy and adverse events data from a phase I trial in Multiple myeloma, Non-Hodgkin's lymphoma and Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)